BioSpace News Archive

Inspire Medical Systems, Inc. today announced certain preliminary, unaudited results for the quarter and full year ended December 31, 2022.

AIM ImmunoTech Inc. today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has granted a utility patent covering rugged dsRNA, a double-stranded RNA product related to Ampligen® (rintatolimod), which claims cover, among other aspects, compositions and compositions for use in the prevention or treatment of COVID-19.

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today highlighted the company’s key 2023 milestones ahead of its presentation at J.P. Morgan’s 41st annual healthcare conference this week.

Solid Biosciences Inc. today announced the appointment of Kevin Tan, CFA, a seasoned industry professional, as Chief Financial Officer.

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”) today announced it has signed an agreement with the Soroka University Medical Center, in Be’er-Sheva, Israel (“Soroka Medical Center”) to conduct the Company’s clinical study for SCI-210 in patients suffering from autism spectrum disorder (“ASD”).

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced that it has extended the Rostock International Parkinson’s Disease Study to recruit and genetically test additional patients over the next few years.

NGM Biopharmaceuticals, Inc. is providing an overview of highlights from 2022 and outlining its 2023 corporate priorities.

Telesis Bio Inc., a leader in automated multi-omic and synthetic biology solutions, pre-announced certain preliminary, unaudited financial results for the fourth quarter ended December 31, 2022.

SomaLogic, Inc., a leader in proteomics technology, announced that preliminary, unaudited revenue for the full year 2022 is expected to be at the high end of its guidance range of $93 to $98 million, reflecting approximately 20% year-over-year revenue growth.

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced an agreement with Amgen, a global biopharmaceutical company, to whole-genome sequence approximately 35,000 DNA samples.